Substudy 02D
Stage/indication incl. Brief info
Melanoma - 1st and 2nd line
Melanoma with 1-5 measurable brain metastases
Anti-PD1 +
antiCTLA4 +
lenvatinib vs
antiPD1 +
lenvatinib
Short title
Merck MK3475
Substudy 02D
(UmbrellaTrial)
NCT04700072
Official title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma: Substudy 02D